Carotuximab

N/A

Report date: 2026/02/07 20:00:33

Base Information

Drug NameCarotuximab
Drug Alias NameDE-122TRC-105NSC#754227Chimeric Antibody TRC-105ENV-105
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibody
Mechanisms of ActionAngiogenesis inhibitorsAnti-CD105
TargetsEndoglin
Therapy Area/IndicationsMetastatic breast cancerSolid tumoursMacular Degeneration +[32] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaUnited StatesTaiwan +[13] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesRoswell Park Cancer Institute
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of Alabama At BirminghamEnviro Therapeutics IncKairos Pharma Ltd
Inactive CompaniesSanten IncRoswell Park Cancer InstituteTracon Pharmaceuticals Inc +[4] 
Active IndicationsProstatic Neoplasms, Castration-ResistantProstatic NeoplasmsCarcinoma, Non-Small-Cell Lung +[5] 
Inactive IndicationsMetastatic breast cancerSolid tumoursMacular Degeneration +[27] 

Other Information

ATC CodeN/A
Related LinksN/A